The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Member discount codes
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Antibodies in late-stage clinical studies

Antibodies in late-stage clinical studies

The remarkable increase in the number of antibody therapeutics in late-stage clinical studies that occurred between 2010 and 2021 has been documented in the ‘Antibodies to watch‘ article series, which describes monoclonal antibodies in late-stage clinical studies (i.e., pivotal Phase 2, Phase 2/3 or Phase 3). All articles in the series were published in mAbs, and they are all freely available.

The table below is derived from data included in the latest article in the series, Antibodies to Watch in 2022, published in January 2022. The Antibody Society will update the data every quarter during 2022. Last table update: November 4, 2022.
Data for antibody therapeutic products that have advanced to regulatory review or approval in any country have been excluded from this table, but they are included in a searchable table that can be found here.

Biosimilar antibodies have been excluded from both tables.

Format and Fc modification data were compiled by Drs. Alicia Chenoweth and Silvia Crescioli, King’s College London, who also built the data table below.

Please cite our data as follows: The Antibody Society. Antibody therapeutics in late-stage clinical studies. (date accessed); www.antibodysociety.org/antibodies-in-late-stage-clinical-studies/

INNDrug Code(s)TargetFormatSpecificityBackboneLight ChainConjugations/FusionMutations/ModificationsPhase of Clinical DevelopmentLate-stage Clinical Study IndicationsTherapeutic AreaCompanyLicensee/Partner 
ZolbetuximabiMAB362, Claudiximab, GC-182Claudin-18.2Chimeric mAbMonospecificIgG1kappaNone foundPhase 3Gastric and gastro-esophageal junction adenocarcinoma (NCT03504397, NCT03653507)CancerAstellas
ZiltivekimabCOR-001IL-6Human mAbMonospecificIgG1kappaM252Y S254T T256E. Enhanced half life Phase 3Atherosclerotic cardiovascular disease, chronic kidney disease (NCT05021835)Cardiovascular/hemostasisAstraZenecaNovo Nordisk A/S
Zilovertamab vedotinMK-2140ROR1Humanized mAbMonospecificIgG1kappaMMAENone foundPhase 2/3Diffuse large B-cell lymphoma (NCT05139017)CancerMerck Sharp & Dohme LLC
ZilovertamabUC-961ROR1Humanized mAbMonospecificIgG1kappaNone foundPhase 3Mantle cell lympoma (NCT05431179)CancerOncternal Therapeutics
ZanidatamabZW25HER2, HER2 (biparatopic)Humanized scFv-Fc(G1) x Fab-FcBispecific; scFv-Fc(G1) x Fab-FcIgG1kappaHetero HH: T350V-L351Y-F405A-Y407V x
T350V-T366L-K392L-T394W
Phase 2 (pivotal) and Phase 3Biliary tract cancers (NCT04466891); Gastroesophageal adenocarcinoma cancer (NCT05152147; HERIZON-GEA-01)CancerZymeworksBeiGene, Jazz Pharmaceuticals plc
Zamerovimab + mazorelvimabSYN023 (mixture of CTB011 + CTB012)Rabies virus spike glycoproteinMixture of 2 humanized mAbsTwo monospecific mAbsIgG1kappaNone foundPhase 3Rabies (NCT04644484)Infectious diseaseSynermore Biologics Co. Ltd.
ZalifrelimabAGEN1884CTLA-4Human mAbMonospecificIgG1kappaNone foundPhase 2 (pivotal)Cervical cancer (NCT03894215)CancerAgenus Inc.Betta Pharmaceuticals, Recepta biopharma
XeligekimabGR1501IL-17AHuman mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Plaque psoriasis (ChiCTR2100043223)Immune-mediated disordersGenrix (Shanghai) Biopharmaceutical Co. Ltd.
VunakizumabSHR-1314IL-17AHumanized mAbMonospecificIgG1kappaNone foundPhase 2/3 and Phase 3Ankylosing spondylitis (NCT04840485);
Plaque psoriasis (NCT04839016)
Immune-mediated disordersAtridia Pty Ltd./ Jiangsu Hengrui Medicine Co.
Vobramitamab duocarmazineMGC018B7-H3Humanized mAbMonospecificIgG1kappaDuocarmycinNone foundPhase 2/3 pendingProstate cancer (NCT05551117 TAMARACK) CancerMacrogenics
VilobelimabBDB-001, IFX-1, CaCP29Complement 5aChimeric mAbMonospecificIgG4kappaNone foundPhase 2/3Pyoderma gangraenosum; COVID-19 (NCT04449588)HemostasisInflarxStaidson (Beijing) Biopharmaceuticals Co., Ltd
VibostolimabMK-7684TIGITHumanized mAbMonospecificIgG1kappaNone foundPhase 3Non-small cell lung cancer (NCT04738487; NCT05298423; NCT05226598); Small cell lung cancer (NCT05224141)CancerMerck Sharp & Dohme Corp.
Upifitamab rilsodotinXMT-1536NaPi2bHumanized mAbMonospecificIgG1kappaAuristatin F-hydroxypropylamideNone foundPhase 3Ovarian cancer (NCT05329545)CancerMersana Therapeutics
Tusamitamab ravtansineSAR408701CEACAM5Humanized mAbMonospecificIgG1kappaDM4None foundPhase 3Non-small cell lung cancer (NCT04154956)CancerImmunoGenSanofi
Trastuzumab rezetecanSHR-A1811HER2mAbMonospecificIgG1kappaRezetecanNone foundPhase 3Breast cancer (NCT05424835)CancerJiangsu HengRui Medicine Co., Ltd.
TozorakimabMEDI3506IL-33Human mAbMonospecificIgG1lambda2None foundPhase 3Chronic obstructive pulmonary disease (NCT05166889, NCT05158387); Acute respiratory failure (NCT05624450 not yet recruiting)RespiratoryAstraZeneca/MedImmune
TosatoxumabAR-301, KBSA301S. aureus alpha-toxinHuman mAbMonospecificIgG1lambdaNone foundPhase 3Ventilator-associated pneumonia caused by S. aureus (NCT03816956)Infectious diseaseKenta Biotech LtdAridis Pharmaceuticals, Serum AMR
TiragolumabMTIG7192A, RO7092284, RG6058TIGITHuman mAbMonospecificIgG1kappaNone foundPhase 3Non-small cell lung cancer (NCT04294810, NCT04513925); Esophageal cancer (NCT04543617, NCT04540211)CancerGenentech
Telisotuzumab vedotinABBV-399cMetHumanized mAbMonospecificIgG1kappaMMAEK222C T223del T225del K447del Phase 3Non-small cell lung cancer (NCT04928846)CancerAbbVie
TebotelimabMGD013PD-1 , LAG-3Humanized DART®; Tandem domain-exchanged FvBispecificIgG4kappaM252Y S254T T256E (half-life extension) Phase 2/3Gastric cancer (NCT04082364)CancerMacrogenicsZai Lab
TarlatamabAMG757DLL3, CD3scFv-scFv-scFcBispecificIgG1R292C N297G V302C (reduced effector function, stabilization)Phase 2 (potentially pivotal)Small cell lung cancer (NCT05060016)CancerAmgen
Tarcocimab tedromerKSI-301VEGFHumanized mAbMonospecificIgG1kappaAntibody-biopolymer
conjugate (site-specific conjugation of an 800 kDa branched phosphorylcholine biopolymer)
Fc mutations for inert effector function and site specific conjugationPhase 3Diabetic macular edema (NCT04603937, NCT04611152); Macular edema due to retinal vein occlusion (NCT04592419);
Wet macular degeneration (NCT04964089); Non-proliferative diabetic retinopathy (NCT05066230)
Ophthalmic disordersKodiak Sciences Inc
SuvratoxumabAR-320, MEDI4893Staphylococcus aureus alpha toxinHuman mAbMonospecificIgG1kappaM252Y S254T T256E. Enhanced half life Phase 3 pendingVentilator Associated Pneumonia caused by Staph aureus (NCT05331885)Infectious diseaseAstraZenecaAridis
SuciraslimabSM03CD22Chimeric mAbMonospecificIgG1kappaNone foundPhase 3Rheumatoid arthritis (NCT04312815)Immune-mediated disordersShenzhen Lonn RyonnSinoMab BioScience Limited 
SolanezumabLY-2062430, hM266.2Amyloid beta, solubleHumanized mAbMonospecificIgG1kappaNone foundPhase 2/3 and Phase 3Alzheimer's disease (NCT01760005);
Cognition disorders (NCT02008357)
Neurological disordersEli Lilly and Company
SibeprenlimabVIS649APRILHumanized mAbMonospecificIgG2kappaNone foundPhase 3 IgA nephropathy (NCT05248646; NCT05248659)Immune-mediated disordersOtsuka Pharmaceutical
SetrusumabUX143, BPS804, MOR05813 SclerostinHuman mAbMonospecificIgG2lambdaNone foundPhase 2/3Osteogenesis imperfecta (NCT05125809)Musculoskeletal disordersUltragenyx Pharmaceutical IncMereo BioPharma
SemzuvolimabUB-421, dB4C7CD4Humanized mAbMonospecificIgG1kappaN297H (Fc-aglycosylated to remove Fc effector function)Phase 3HIV infection (NCT04406727, NCT03149211)Infectious diseaseUnited Biopharma
SasanlimabPF-06801591PD-1Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Non-muscle invasive bladder cancer (NCT04165317)CancerPfizer
SabatolimabMBG453TIM-3Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Myelodysplastic syndromes and chronic myelomonocytic leukemia (NCT04266301)CancerNovartis
RulonilimabF520PD-1Chimeric mAbMonospecificIgG1kappaT250Q N297A M428L; Reduced effector function, increased half-lifePhase 2/3 pendingHepatocellular carcinoma (NCT05408221)CancerShandong New Time Pharmaceutical Co., LTD
Rosopatamab (177Lu-DOTA)TLX591, ATL-101, Lu-177-huJ591PSMAHumanized mAbMonospecificIgG1kappaConjugated to Lu-177None foundPhase 3 pendingProstate cancer (NCT04876651)CancerTelix Pharmaceuticals
RocatinlimabKHK4083, AMG451OX40Human mAbMonospecificIgG1kappaNone foundPhase 3 Atopic dermatitis (NCT05398445)Immune-mediated disordersKyowa Hakko KirinAmgen
Retlirafusp alfaSHR-1701PD-L1, TGF-β Antibody-receptor fusionBispecificIgG4kappaExtracellular domain of human TGF-β receptor IIS228P (hinge-stabilization)Phase 2/3; Phase 3 Cervical cancer (NCT05179239); Colorectal cancer (NCT04856787); Gastric or gastroesophageal junction cancer (NCT04950322); Non-small cell lung cancer (NCT05132413 (not yet recruiting))CancerJiangsu HengRui Medicine Co., Ltd.Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RecaticimabSHR-1209PCSK9HumanizedmAbMonospecificIgG1kappaM252Y, S254T, T256E (half life extension)Phase 3Hypercholesterolemia and hyperlipidemia (NCT04849000, NCT04885218);
Primary hypercholesterolemia (NCT04844125)
Cardiovascular / hemostasisJiangsu HengRui Medicine Co., Ltd.
QuavonlimabMK-1308, AK107CTLA-4Humanized mAbMonospecificIgG1kappaNone foundPhase 3Renal cell carcinoma (NCT04736706)CancerAkeso BiopharmaMerck Sharp & Dohme Corp.
PozelimabREGN3918Complement C5Human mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 2/3 and 3CD55-deficient protein-losing enteropathy (NCT04209634); Paroxysmal nocturnal hemoglobinuria (NCT04162470, NCT05133531);
Generalized myasthenia gravis (NCT05070858)
Cardiovascular / hemostasisRegeneron
Pivekimab sunirineIMGN632CD123Humanized mAbMonospecificIgG1kappaDGN549 IGNS442C (site-specific)Phase 2 (pivotal)Blastic plasmacytoid dendritic cell neoplasm (NCT03386513 CADENZA)CancerImmunoGen
Patritumab deruxtecanU3-1402HER3Human mAbMonospecificIgG1kappaDXd/DX-8951None foundPhase 3Epidermal growth factor receptor-mutated non-small cell lung cancer (NCT05338970)CancerDaiichi Sankyo Co., Ltd
ParidiprubartEB05, NI-0101Toll-like receptor 4Humanized mAbMonospecificIgG1kappaN325S L328FPhase 2/3COVID-19-related acute respiratory distress syndrome (NCT04401475)RespiratoryNovImmune SAEdesa Biotech
PamrevlumabFG-3019Connective tissue growth factorHuman mAbMonospecificIgG1kappaNone foundPhase 3Duchenne muscular dystrophy (NCT04632940, NCT04371666); Idiopathic pulmonary fibrosis (NCT04419558, NCT03955146);
Pancreatic cancer (NCT03941093, NCT04229004)
Musculoskeletal disorders (secondary areas: Respiratory, Cancer)FibroGen
OtilimabGSK3196165, MOR103, MOR-04357GM-CSF (aka CSF2)Human mAbMonospecificIgG1lambdaNone foundPhase 3Rheumatoid arthritis (NCT03980483, NCT03970837, NCT04134728, NCT04333147)Immune-mediated disordersMorphoSys AGGlaxoSmithKline
OregovomabMab-B43.13CA125Murine mAbMonospecificIgG1kappaNone foundPhase 3Ovarian cancer (NCT04498117)CancerQuest PharmaTech Inc.OncoQuest Pharmaceuticals, Inc.
OngericimabJS002PCSK9Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Heterozygous familial hypercholesterolemia (NCT05325203); Hyperlipidemia (NCT04781114; NCT05532800)Cardiovascular / hemostasisShanghai Junshi Bioscience Co Ltd
Onfekafusp alfaL19TNF, L19(scFv)2-TNFFibronectin extra-domain BHuman scFv fused with TNFMonospecificscFv fused with TNFkappascFv fused with TNFNone foundPhase 3Soft tissue sarcoma (NCT04650984); melanoma (NCT03567889, in combination with L19IL2)CancerPhilogen S.p.A.
OleclumabMEDI9447CD73Human mAbMonospecificIgG1lambda1L234F L235E P331S. Reduced effector functionPhase 3Non-small cell lung cancer (NCT05221840)CancerAstraZeneca
OdronextamabREGN1979CD20, CD3Human mAbBispecificIgG4; Hetero H, cLkappaHetero HH: WT x H435R-Y436F (limits binding to Protein A, purification);
HL-pairing: cL ; both chains: E233P, F234V, L235A, G236del
(Fc-silencing), S228P (hinge-stabilization)
Phase 2 (potentially pivotal)Non-Hodgkin lymphoma (NCT03888105)CancerRegeneronZai Lab
OciperlimabBGB-A1217TIGITHumanized mAbMonospecificIgG1kappaNone foundPhase 3Non-small cell lung cancer (NCT04746924, NCT04866017)CancerBeiGene
NofazinlimabCS1003PD-1Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Hepatocellular carcinoma (NCT04194775)CancerCstone PharmaceuticalsEQRx
NipocalimabM281FcRnHuman mAbMonospecificIgG1lambdaN297A (Fc-aglycosylated)Phase 2/3 and Phase 3Warm autoimmune hemolytic anemia (NCT04119050);
Generalized myasthenia gravis (NCT05265273, NCT04951622) ; Polyradiculoneuropathy (NCT05327114)
Immune-mediated disordersJanssen
NavicixizumabOMP-305B83DLL4, VEGFHumanized, chimeric mAbBispecificIgG2; Hetero H, cLkappaHetero HH: L368E-Y407E x T357K-D399K (bispecific assembly) ;
HL-pairing: cL
Phase 3 pendingOvarian cancer/peritoneal cancer/fallopian tube cancer (NCT05043402 (not yet recruiting))CancerOncXerna Theraputics, Inc.
NadunolimabCAN04IL1 Receptor Accessory ProteinHumanized mAbMonospecificIgG1kappaNone foundPhase 2/3 pendingPancreatic cancer (NCT04229004)CancerCantargia ABPancreatic Cancer Action Network
MonalizumabNN8765, IPH-2201, NNC141-0100NKG2AHumanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Squamous Cell Carcinoma of the Head and Neck (NCT04590963)CancerNovo NordiskAstraZeneca; Innate Pharma
Mecbotamab vedotinBA3011, HTBA3011, CAB-AXL-ADCAXL receptor tyrosine kinaseHumanized mAbMonospecificIgG1kappaMMAENone foundPhase 2 (potentially pivotal)Soft tissue and primary bone sarcoma (NCT03425279)CancerBioAlta LLCHimalaya Therapeutics
MarstacimabPF-06741086Tissue factor pathway inhibitorHuman mAbMonospecificIgG1lambdaL234A, L235A, G237A (impair Fc effector funcctions)Phase 3Severe hemophilia A or B (NCT05145127, NCT03938792)Cardiovascular / hemostasisPfizer
MagrolimabONO-7913, Hu5F9-G4CD47Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Myelodisplastic syndromes (NCT04313881); Acute myeloid leukemia (NCT04778397, NCT05079230) CancerGilead SciencesOno Pharmaceutical Co
LitifilimabBIIB059Blood dendritic cell antigen 2 (CD303; CLEC4C)Humanized mAbMonospecificIgG1kappaNone foundPhase 2/3 and Phase 3Cutaneous lupus erythematosus (NCT05531565); Systemic lupus erythematosus (NCT05352919, NCT04961567, NCT04895241)Immune-mediated disordersBiogen
LinvoseltamabREGN5458BCMA, CD3Human mAbBispecificIgG4; Hetero H, cL kappaHetero HH: WT x H435R-Y436F (limits binding to Protein A, purification);
HL-pairing: cL; both chains: E233P, F234V, L235A, G236del
(Fc-silencing)
Phase 2 (potentially pivotal)Multiple myeloma (NCT03761108)CancerRegeneron
LigelizumabQGE031IgEHumanized mAbMonospecificIgG1kappaNone foundPhase 3Chronic spontaneous urticaria (NCT03580356, NCT03580369, NCT03907878, NCT04210843);
Chronic inducible urticaria (NCT05024058);
Peanut allergy (NCT04984876)
Immune-mediated disordersTanoxNovartis
LatozinemabAL001SortilinHuman mAbMonospecificIgG1kappaL234A, L235A, P331S (remove Fc effector functions)Phase 3Frontotemporal dementia (NCT04374136)Neurological disordersAlectorGlaxoSmithKline
IzalontamabSI-B001EGFR, HER3IgG-(scFv)2BispecificIgG1kappaNone foundPhase 2/3Non-small cell lung cancer (NCT05020457, NCT05020769)CancerBiokinSichuan Baili Pharmaceutical Co. Ltd, SystImmune Inc.
IvuxolimabPF-04518600OX40Human mAbMonospecificIgG2kappaNone foundPhase 3Advanced malignancies (NCT05059522)CancerPfizer Inc.
IvonescimabAK112PD-1, VEGFmAbBispecificIgG1-(scFv2)kappaL234A L235A (reduced effector function) Phase 3Non-small cell lung cancer (NCT05184712, NCT05499390 (not yet recruiting))CancerAkesobio Australia Pty Ltd
ItepekimabREGN3500, SAR440340IL-33Human mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Chronic obstructive pulmonary disease (NCT04751487, NCT04701983)RespiratoryRegeneronSanofi
Iparomlimab (anti-PD-1), Tuvonralimab (anti-CTLA-4)QL1706PD-1, CTLA-4mAbsMixture of 2 monospecific antibodiesIgG4 (anti-PD-1); IgG1 (anti-CTLA4)kappaS228P IgG4 hinge stabilization; K147D F170C V173C C220G R255K D399R K409E IgG1 mutations (heterodimerization)Phase 3Nasopharyngeal carcinoma (NCT05576272); Non-small cell lung cancer (NCT05487391 (not yet recruiting)); Cervical cancer (NCT05446883)CancerQilu Pharmaceutical Co., Ltd.
InclacumabRO4905417, RG1512P-selectin (CD62)Human mAbMonospecificIgG4kappaS228P (hinge-stabilization); L235E (impair Fc effector function)Phase 3 Vaso-occlusive crisis in sickle cell disease patients (NCT05348915, NCT04927247, NCT04935879)Cardiovascular / hemostasisHoffmann-La Roche; GenmabGlobal Blood Therapeutics
ImsidolimabANB019IL-36RHumanized mAbMonospecificIgG4kappaS228P. Hinge stabilization Phase 3Generalized pustular psoriasis (NCT05352893, NCT05366855)Immune-mediated disordersAnaptysBio, Inc.
IanalumabVAY736BLyS/BAFF/TACI/BCMA receptorHuman mAbMonospecificIgG1kappaAfucosylated (improve FcγRIIIa binding/improve ADCC)Phase 2/3 and Phase 3Sjogren syndrome (NCT05350072, NCT05349214); Autoimmune hepatitis (NCT03217422); Lupus nephritis (NCT05126277); Systemic Lupus Erythematosus (NCT05624749 not yet recruiting)Immune-mediated disordersMorphoSysNovartis
GlenzocimabACT017Glycoprotein VI on plateletsHumanized FabMonospecificIgG1kappaNone foundPhase 2/3Acute ischemic stroke (NCT05070260)Cardiovascular diseaseActicor Biotech
GefurulimabALXN1720Complement 5, albuminVH - VH'BispecificVH - VH'None foundPhase 3Generalized myasthenia gravis (NCT05556096)Neuromuscular disordersAlexion Pharmaceuticals, Inc.
GaretosmabREGN2477Activin AHuman mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Fibrodysplasia ossificans progressiva (NCT05394116)Musculoskeletal disordersRegeneron
GaradacimabCSL312Factor XIIaHuman mAbMonospecificIgG4lambdaS228P (hinge-stabilization)Phase 3Prevention of hereditary angioedema attacks (NCT04656418, NCT04739059) Cardiovascular / hemostasisCSL Behring
GantenerumabRO4909832, RG1450Amyloid betaHuman mAbMonospecificIgG1kappaNone foundPhase 3Early Alzheimer's disease (NCT05256134, NCT05552157, NCT01760005, NCT03444870, NCT03443973);
Alzheimer's disease (NCT04339413, NCT04374253)
Neurological disordersHoffmann-La RocheMorphoSys
Futuximab+modotuximabSYM004EGFRChimeric mAbsMixture of 2 monospecific mAbsIgG1kappaNone foundPhase 3Colorectal cancer (NCT05223673)CancerInstitut de Recherches Internationales Servier
FinotonlimabSCT-I10A, SCTI-10APD-1Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 2/3 and Phase 3Hepatocellular carcinoma (NCT04560894); Non-small-cell lung cancer (NCT04171284); Head and neck squamous cell carcinoma (NCT04146402)CancerSinocelltech Ltd
FianlimabREGN3767LAG-3Human mAbMonospecificIgG4kappaS228P; E233P F234V L235A G236del. Hinge stabilization and reduced effector function Phase 3Melanoma (NCT05352672, NCT05608291 not yet recruiting)CancerRegeneron PharmaceuticalsSanofi
FelzartamabTJ202, MOR202, MOR03087CD38Human mAbMonospecificIgG1lambdaNone foundPhase 3Multiple myeloma (NCT03952091)CancerMorphoSys AGI-Mab Biopharma
FavezelimabMK-4280LAG-3Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 3Hodgkin lymphoma (NCT05508867); Colorectal cancer (NCT05600309, NCT05064059)CancerMerck Sharp & Dohme Corp.
ErfonrilimabKN046PD-L1, CTLA4Humanized, chimeric Hetero H; VH-VH-h-CH2-CH3 dimerBispecificIgG1; Hetero H; VH-VH-h-CH2-CH3 dimern/aHetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly)Phase 3Non-small-cell lung cancer (NCT05149326, NCT04474119, NCT05001724)CancerJiangsu Alphamab Biopharmaceuticals Co., Ltd
EmactuzumabRO5509554, RG7155CD115 (aka CSF1 receptor)Humanized mAbMonospecificIgG1kappaNone foundPhase 3Tenosynovial giant cell tumor (NCT05417789)CancerHoffmann-La RocheSynOx Therapeutics
ElranatamabPF-06863135BCMA, CD3Humanized mAbBispecificIgG2kappaStrop Fab-arm exchange method ((WO2016/166629) CD3 antibody: IgG1RRR: 221R, 228R, K409R or IgG2deltaA-RRRR: 223R, 225R, 228R, K409R; Target antibody: IgG1EEE: 221E, 228E, L368E or IgG2deltaA-EEEE: 223E, 225E, 228E, L368E, Exchange with 1-2 mM GSH).
Phase 3Multiple myeloma (NCT05317416, NCT05020236)CancerPfizer
EbronucimabAK102PCSK9Human mAbMonospecificIgG1lambda2None foundPhase 3Primary hypercholesterolemia and mixed hyperlipidemia (NCT05255458, NCT05255094, NCT05260411)Cardiovascular/hemostasisAkesobio Australia Pty LtdDawnrays Pharmaceutical (Holdings) Limited
EbdarokimabAK101IL-12/23p40Humanized mAbMonospecificIgG1kappaNone foundPhase 3Plaque psoriasis (NCT05509361, NCT05120297)Immune-mediated disordersAkesobio Australia Pty Ltd
DomvanalimabAB154TIGITHumanized mAbMonospecificIgG1kappaL234A, L235A (impair Fc effector functions)Phase 3Gastrointestinal tract adenocarcinoma (NCT05568095); Non-small cell lung cancer (NCT05211895, NCT05502237, NCT04736173)CancerArcus BiosciencesGilead Sciences
DivozilimabBCD-132CD20Humanized mAbMonospecificIgG1kappaNone foundPhase 3Multiple sclerosis (NCT05385744)Immune-mediated disordersBiocad
DepemokimabGSK3511294IL-5Humanized mAbMonospecificIgG1kappaM252Y, S254T, T256E (half-life extension)Phase 3Hypereosinophilic syndrome (NCT05334368); Eosinophilic granulomatosis with polyangiitis (NCT05263934); Nasal polyps (NCT05274750, NCT05281523); Severe uncontrolled asthma with an eosinophilic phenotype (NCT05243680, NCT04719832, NCT04718103, NCT04718389)Immune-mediated disordersGlaxoSmithKline
Datopotamab deruxtecanDS-1062TROP-2Humanized mAbMonospecificIgG1kappaConjugated to deruxtecan DX-8951 (Topoisomerase I inhibitor)None foundPhase 3Non-small cell lung cancer (NCT05555732, NCT05215340, NCT04656652, NCT05555732); Breast cancer (NCT05374512, NCT05104866)CancerDaiichi-Sankyo
Dapirolizumab pegolCDP-7657CD40LHumanized FabMonospecificIgG1kappaPEGylatedNone foundPhase 3Systemic lupus erythematosus (NCT04976322, NCT04294667)Immune-mediated disordersUCBBiogen
Dafsolimab setaritox + grisnilimab setaritoxT-Guard; SPV-T3a + WT1CD3 + CD7Mixture of two mAb murineTwo monospecific mAbsIgG2b, IgG2a kappa; lambdaConjugated to ricin ANone foundPhase 3Steroid-refractory acute graft vs. host disease (NCT04934670)Immune-mediated disordersXenikos
CoprelotamabGB221HER2Humanized mAbMonospecificIgG1kappaNone foundPhase 3HER2+ Breast cancer (NCT04164615)CancerGenor Biopharma Co., Ltd.
CobolimabGSK4069889, TSR-022TIM-3Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 2/3Non-small cell lung cancer (NCT04655976)CancerGlaxoSmithKline
ClesrovimabMK-1654RSV fusion proteinHuman mAbMonospecificIgG1kappaM252Y, S254T, T256E (half life extension)Phase 2/3 and Phase 3Reduction in incidence of respiratory syncytial virus infection (NCT04767373, NCT04938830)Infectious diseaseMerck Sharp & Dohme Corp.
ClazakizumabALD518; BMS-945429IL-6Humanized mAbMonospecificIgG1kappaN297A (Fc-aglycosylated)Phase 3End-stage kidney disease (NCT05485961 (not yet recruiting)); Antibody-mediated rejection in kidney transplant recipients (NCT03744910)Immune-mediated disordersH. LundbeckVitaeris Bio
CetrelimabJNJ-63723283PD-1Human mAbMonospecificIgG4kappaS228P (hinge-stabilization)Phase 2/3 and Phase 3Urinary bladder neoplasms (NCT04658862)CancerJanssen Research & Development, LLCXOMA Corporation
CendakimabCC-93538, RPC4046; ABT-308, 13C5.5IL-13Humanized mAbMonospecificIgG1kappaL234A, L235A (impair Fc effector functions)Phase 3Eosinophilic gastroenteritis (NCT05214768); Eosinophilic esophagitis (NCT04753697, NCT04991935)Immune-mediated disordersAbbVieBristol-Myers Squibb
Camidanlumab tesirineADCT-301CD25Human mAbMonospecificIgG1kappaConjugated to pyrrolobenzodiazepine dimer SG3249None foundPhase 2 (pivotal)Hodgkin lymphoma (NCT04052997)CancerADC Therapeutics SarlAbbVie
BrazikumabAMG139, MEDI2070IL-23Human mAbMonospecificIgG2lambdaNone foundPhase 2/3 and Phase 3Crohn's disease (NCT03759288, NCT03961815)Immune-mediated disordersAmgenAstraZeneca; AbbVie/Allergan
BirtamimabNEOD001AmyloidHumanized mAbMonospecificIgG1kappaNone foundPhase 3Light chain (AL) amyloidosis (NCT04973137)Immune-mediated disordersOnclave Therapeutics Limited, subsidiary of Prothena
Bintrafusp alfaM7824, MSB0011359CPD-L1, TGFβHuman mAbBispecificIgG1lambdaIgG1 fused with TGFbeta binding domainNone foundPhase 2/3 and Phase 3Biliary tract cancer (NCT04066491); Non-small cell lung cancer (NCT03631706); Follow-up study to collect long-term data on participants from multiple Bintrafusp Alfa clinical studies (NCT05061823)CancerEMD Serono/Merck KGaA
BentracimabPB2452 (formerly MEDI2452)TicagrelorHuman FabMonospecificFab (IgG1 CH1)lambdaNone foundPhase 3Reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure (NCT04286438)Cardiovascular / hemostasisAstraZenecaPhaseBio Pharmaceuticals, Inc., Alfasigma
BemarituzumabFPA144FGFR2bHumanized mAbMonospecificIgG1kappaAfucosylatedPhase 3Gastric cancer/gastroesophageal junction adenocarcinoma (NCT05111626, NCT05052801)CancerAmgenZai Lab
BatoclimabIMVT-1401, RVT-1401, HL161BKN, HBM9161(HL161BKN), HL161FcRnHuman mAbMonospecificIgG1lambdaL234A, L235A (impair Fc effector functions)Phase 3Thyroid eye disease (NCT05517447, NCT05524571, NCT05517421) ; Generalized myasthenia gravis (NCT05403541); Primary immune thrombocytopenic purpura (NCT04428255);
Thyroid opthalmopathy (NCT05015127);
Myasthenia gravis (NCT05332210, NCT05039190)
Immune-mediated disordersHanall Biopharma, a subsidiary of Daewoong Pharmaceutical Co., LtdHarbour BioMed, Roivant Sciences / Immunovant Inc.
Atisnolerbart, bremzalerbart, umesolerbartREGN5713-5714-5715Bet v1Mixture of 3 human mAbsThree monospecific antibodies against three different epitopesIgG4kappaS228P (hinge stabilizing)Phase 3Seasonal allergic rhinitis (NCT04709575)Immune-mediated disordersRegeneron
ApitegromabSRK-015MyostatinHuman mAbMonospecificIgG4lambdaS228P (hinge-stabilization)Phase 3Spinal muscular atrophy (NCT05156320)Muscular diseasesScholar Rock
Apamistamab-Iodine (131I) I-131-BC8, Iomab-BCD45Murine mAbMonospecificIgG1kappaI-131None foundPhase 3Acute myeloid leukemia (NCT02665065)CancerActinium Pharmaceuticals
AnselamimabCAEL-101, Ch mAb 11-1F4Amyloid fibrilChimeric mAbMonospecificIgG1kappaNone foundPhase 3Light chain (AL) amyloidosis (NCT04512235, NCT04504825)Immune-mediated disordersCaelum BiosciencesAstraZeneca
AnbenitamabKN026HER2, HER2 (biparatopic)Humanized mAbBispecificIgG1; Hetero Hkappa (common light chain)Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly)Phase 2/3Gastric/Gastroesophageal junction cancer (NCT03925974, NCT05427383)CancerJiangsu Alphamab Biopharmaceuticals Co., Ltd Sanofi
AdebrelimabSHR-1316, HTI-1088PD-L1Humanized mAbMonospecificIgG4kappaS228P (hinge-stabilization), F234A, L235A (abrogate effector function)Phase 3Non-small cell lung cancer (NCT04316364); Small cell lung cancer (NCT04691063, NCT03711305) CancerJiangsu Hengrui Medicine Co.Atridia Pty Ltd.
AbelacimabMAA868Factor XIHuman mAbMonospecificIgG1lambdaD265A P329A. Reduced effector functions Phase 3 Venous thromboembolism (NCT05171075, NCT05171049)Cardiovascular/hemostasisNovartisAnthos Therapeutics, MorphoSys
APX003, BD0801, TK001, sevacizumabVEGFHumanized mAbMonospecificPhase 3Ovarian cancer (NCT04908787)CancerJiangsu Simcere Pharmaceutical Co., Ltd.Apexigen
AFM13CD30, CD16AHuman mAb; TandAb (tetravalent bispecific molecule comprising antibody variable domains with two binding sites for each antigen)Bispecific; Tetravalent--Phase 2 (pivotal)Peripheral T-cell lymphoma or transformed mycosis fungoides (NCT04101331)CancerAffimed
ANX005Complement C1qHumanized mAbMonospecificIgG4Phase 2/3Guillain-Barré syndrome (NCT04701164)Cardiovascular / hemostasisAnnexon Biosciences
ARX788HER2Humanized mAbMonospecificIgG1Amberstatin 269 (Auroxime)Phase 2 (pivotal), Phase 2/3, Phase 3Breast cancer (NCT05426486, NCT04829604, ACE-Breast-02 (China)); Gastric cancer (ACE-Gastric-02 (China))CancerAmbrxNovoCodex Biopharmaceuticals Co. Ltd, Zhejiang Medicine Co. Ltd
CBT-502, TQB2450, APL-502PD-L1Humanized mAbMonospecificIgG1Fc silencedPhase 3Ovarian cancer (NCT05145218) Renal cancer (NCT04523272); Non-small cell lung cancer (NCT05346952, NCT04325763, NCT04964479); Squamous cell carcinoma of the head and neck (NCT03855384); Biliary cancer (NCT04809142)CancerCBT Pharmaceuticals, IncChia Tai Tianqing Pharmaceutical Group Co., Ltd.
IBI310CTLA-4Humanized mAbMonospecificIgG1Phase 3Melanoma (NCT04277663); Hepatocellular carcinoma (NCT04720716)CancerInnovent Biologics, Inc
INBRX-109DR5Humanized mAb; sdAb (heavy chain only antibodies) fused to FcMonospecific; TetravalentIgG1Fc silencedPhase 2 (potentially pivotal)Chondrosarcoma (NCT04950075)CancerInhibrx, Inc.
JY-025VEGFR2Human mAbMonospecificPhase 2/3 pendingNon-small cell lung cancer (NCT04874844 (not yet recruiting))CancerBeijing Dongfang Biotech Co., Ltd.
MIL62CD20Humanized mAbMonospecificIgG1kappaAfucosylatedPhase 3Neuromyelitis optica spectrum disorder (NCT05314010); Follicular lymphoma and marginal zone lymphoma (NCT04834024)CancerBeijing Mabworks Biotech Co., Ltd.
NIS793, XOMA-089TGF beta 1 and 2Human mAbMonospecificIgG2Phase 3Pancreatic ductal adenocarcinoma (NCT04935359)CancerXOMA CorporationNovartis
NNC0365-3769, Mim8FIXa, FXHuman mAbBispecificIgG4Phase 3Hemophilia A with or without inhibitors (NCT05306418, NCT05053139)Cardiovascular / hemostasisNovo Nordisk A/S
QL1604PD-1mAbMonospecificPhase 2/3Cervical cancer (NCT04864782)CancerQilu Pharmaceutical Co., Ltd.
RO7204239, GYM329, RG6237MyostatinHumanized mAbMonospecificIgG1Specific mutations not found; engineered for selective and enhanced binding to the human
FcγRIIb and for stronger affinity to FcRn in acidic pH conditions
Phase 2/3Spinal muscular atrophy (NCT05115110)Musculoskeletal disordersChugaiRoche
MAD0004J08SARS-CoV-2Human mAbMonospecificIgG1M428L /N434S (extends half-life) L234A/L235A/P329G (impair Fc effector functions)Phase 2/3COVID-19/SARS-CoV-2 infection (NCT04952805)Infectious diseaseToscana Life Sciences Sviluppo s.r.l.
ADM03820 (COV2-2130-YTE-LALA + COV2-2381-YTE124 LALA)SARS-CoV-2Mixture of 2 human mAbsTwo monospecific antibodiesIgG1M252Y/S254T/T256E (extends half-life); L234A/L235A (reduces Fc effector functions)Phase 2/3 pendingCOVID-19/SARS-CoV-2 infection (NCT05142527)Infectious diseaseOlogy Bioservices / Evotec
LMN-201Campylobacter jejuni and enterotoxigenic E. coli exotoxin TcdBMixture of 3 VHH homodimersThree monospecific nanobodiesVHH homodimersPhase 2/3 pendingClostridioides difficile infection (NCT05330182)Infectious diseaseLumen Bioscience, Inc.
HP6H8, meplazumabCD147Humanized mAbMonospecificIgG2Phase 2/3COVID-19 (NCT05113784, NCT04586153)Infectious diseaseJiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
E2814TauHumanized mAbMonospecificIgG1Phase 2/3Dominantly inherited Alzheimer's Disease (NCT05269394)Neurological disordersEisai Co., Ltd.
CM310IL-4RαHumanized mAbMonospecificPhase 3 pendingChronic Rhinosinusitis with nasal polyposis (NCT05436275 not yet recruiting)
Atopic dermatitis (NCT05265923 not yet recruiting)
Immune-mediated disordersKeymed Biosciences Co. Ltd
SKB264Trop-2mAbMonospecificBelotecan-derived payloadPhase 3 pendingTriple-neg. breast cancer (NCT05347134)CancerSichuan Kelun Pharmaceutical Research Institute Co., Ltd.
601VEGFHumanized mAbMonospecificPhase 3Branch retinal vein occlusion (NCT05520177)Ophthalmic disordersSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
9MW0211VEGFmAbMonospecificPhase 2/3Wet age-related macular degenerationOphthalmic disordersMabwell (Shanghai) Bioscience Co., Ltd.Apexigen
CBP-201IL-4R alphamAbMonospecificPhase 2 (pivotal), Phase 3 pendingAtopic dermatitis (NCT05017480, NCT05614817 not yet recruiting)Immune-mediated disordersSuzhou Connect Biopharmaceuticals, Ltd.
CTX-009, ES104, TR009, NOV1501, ABL001VEGF-A, DLL4 mAbBispecificPhase 2/3Biliary tract cancers (NCT05506943) CancerNational OncoVenture Compass Therapeutics, Inc., Elpiscience Biopharmaceuticals, ABL Bio Inc.
GLS-010PD-1Human mAbMonospecificPhase 3 pendingHodgkin lymphoma (NCT05518318) CancerHarbin Gloria PharmaceuticalsArcus Biosciences
AxatilimabSNDX-6352CSF-1RHumanized mAbMonospecificIgG4kappaS228P (hinge stabilizing)Phase 2 (pivotal)Chronic Graft-versus-host-disease (NCT04710576)Immune-mediated disordersSyndax Pharmaceuticals, IncIncyte
AstegolimabRO7187807, MSTT1041A, RG6149, AMG282IL-33RmAbMonospecificIgG2kappaNone foundPhase 2/3Chronic obstructive pulmonary disease (NCT05595642)RespiratoryHoffmann-La Roche
RO7200220IL-6Humanized mAbMonospecificIgG2Phase 3Uveitic macular edema (NCT05642325, NCT05642312)Ophthalmic disordersHoffmann-La Roche
Picankibart, IBI112IL-23p19Humanized mAbMonospecificFc engineered for half-life extensionPhase 3 pendingPsoriasis (NCT05645627)Innovent Biologics (Suzhou) Co. Ltd.
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals